Leerink Still Sees VIVUS's (VVUS) Qnexa as 'Obesity Therapy of Choice'

Article Stock Quotes (2) Comments (0)

Following an FDA Panel's backing of Arena's (Nasdaq: ARNA) lorcaserin Thursday afternoon and the resulting 60 percent surge in the stock this morning, Leerink Swann's Steve Yoo said VIVUS's (Nasdaq: VVUS) Qnexa will still be the "obesity therapy of choice" even if lorcaserin is approved. The analyst noted not only is Qnexa more effective, it will likely be the first of the diet pills on the US market. He also pointed out patients taking lorcaserin will be required to undergo echocardiogram every six months to year.

Yoo maintains an Outperform rating on VIVUS shares.

Visit our Analyst Ratings page to track all the market-moving analyst calls on shares of VIVUS.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Needham & Company Lifts Numbers on Marvell (MRVL) on Solid Results
• Sarissa Capital Shows New 1.99% Stake in Vivus, Inc. (VVUS), Denner Nominated to Board
• Pandora (P) Posts 'Strong Quarter' - Needham & Company

Create E-mail Alert Related Categories

Analyst Comments

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?